Amarin Corp Plcuk (AMRN) Cash from Operations Growth (3y) (2013 - 2026)
Amarin Corp Plcuk (AMRN) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 27.24% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -18.38% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 13.18% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 18.04% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -0.88% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 15.19% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 39.10% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | -2.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.86% |
| Mar 31, 2026 | 42.79% |
| Dec 31, 2025 | 114.32% |
| Sep 30, 2025 | 11.33% |
| Jun 30, 2025 | 31.18% |
| Mar 31, 2025 | 49.86% |
| Dec 31, 2024 | 22.18% |
| Sep 30, 2024 | 19.59% |
| Jun 30, 2024 | 43.27% |
| Mar 31, 2024 | 12.34% |
| Dec 31, 2023 | 74.37% |
| Sep 30, 2023 | -12.27% |
| Jun 30, 2023 | 65.58% |
| Mar 31, 2023 | -54.58% |
| Dec 31, 2022 | 29.54% |
| Sep 30, 2022 | -41.57% |
| Jun 30, 2022 | -82.31% |
| Mar 31, 2022 | -37.42% |
| Dec 31, 2021 | 4.38% |
| Sep 30, 2021 | 45.57% |